| Nov 20 |
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
|
| Nov 19 |
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
|
| Nov 19 |
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
|
| Nov 18 |
TenNor’s Phase III antibiotic trial meets all primary endpoints
|
| Nov 18 |
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
|
| Nov 17 |
Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 14 |
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 14 |
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 13 |
Spero Therapeutics Q3 2024 Earnings Preview
|
